We evaluated a serial change in peripheral neuropathy (PN) severity during treatment with bortezomib (Bor) or lenalidomide (Len) using the Functional Assessment of Cancer Therapy scale/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx). The patient suffered from grade 2 PN and exhibited a dramatic decrease in FACT/GOG-Ntx score after intravenous and subcutaneous Bor therapy. Thereafter, he received seven cycles of Len therapy, which exacerbated existing PN; he experienced mild numbness and exhibited a transient decrease in FACT/GOG-Ntx score. Interestingly, FACT/GOG-Ntx score increased to baseline and numbness was ameliorated during the Len washout period in every cycle.
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-dependent, nerve-damaging adverse reaction with reported prevalence rates of 68.1% at the first month after starting chemotherapy; 60.0 % at the third month; and 30% at the sixth month.
* A total of 72 breast cancer patients were divided into two groups—one receiving pentoxifylline and the other a placebo—for 12 weeks; results showed a significantly lower incidence of grade 2 or 3 PN in the pentoxifylline group (28.6%) compared to the control group (64.9%).
* Quality of life scores were significantly better in the pentoxifylline group, with worse outcomes reported in the control group, indicating that pentoxify
Objective: To observe the clinical efficacy of electroacupuncture (EA) at frequencies of 2 Hz, 100 Hz, and 2 Hz/100 Hz for chemotherapy-induced peripheral neuropathy (CIPN).
Methods: One hundred and sixty female breast cancer patients with CIPN induced by paclitaxel were randomly divided into a 2 Hz EA group (40 cases, 1 case dropped out), a 100 Hz EA group (40 cases, 2 cases dropped out), a 2 Hz/100 Hz EA group (40 cases, 3 cases dropped out), and a medication group (40 cases, 2 cases dropped out). The three EA groups received acupuncture at bilateral Quchi (LI 11), Waiguan (TE 5), Hegu (LI 4), Zusanli (ST 36), and Yanglingquan (GB 34).
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a significant side effect of some chemotherapeutic agents. Effective treatment is limited.
Objectives: This single patient case details gua sha as an intervention to reduce CIPN.
Importance: Chemotherapy-induced peripheral neuropathy (CIPN) is a substantial adverse effect of anticancer treatments. As such, the assessment of CIPN remains critically important in both research and clinic settings.
Objective: To compare the validity of various patient-reported outcome measures (PROMs) with neurophysiological and sensory functional measures as the optimal method of CIPN assessment.
